What’s the difference between Wixela and Advair?
Wixela Inhub and Advair Diskus are both inhaled combination medicines used to treat asthma and COPD. They contain the same active ingredients: an inhaled corticosteroid (fluticasone) plus a long-acting beta agonist (salmeterol). [1][2]
The main practical difference is that Wixela is marketed as a generic version (same drug components) while Advair is the branded product. [1][2]
Are Wixela and Advair interchangeable?
They’re generally considered therapeutic alternatives because they use the same medicine components (fluticasone/salmeterol) in approved dose strengths. [1][2]
In practice, interchangeability depends on matching:
- The exact dose strength (mcg of fluticasone and mcg of salmeterol per actuation)
- The device type and dosing instructions for that specific product
- Your prescriber’s plan for maintenance control
Switches are most often handled by staying on the same dose strength and reviewing whether the prescription is for Wixela Inhub vs Advair Diskus. [1][2]
Which one is cheaper, and does that affect access?
Cost and insurance coverage are usually the biggest driver. Because Wixela is marketed as a generic, it is commonly priced lower than the branded Advair product, which can improve formulary access for some patients. [1][2]
Do they have the same side effects?
Because Wixela and Advair use the same active ingredients, their side-effect profiles are expected to be similar. That includes risks associated with inhaled corticosteroids (such as oral/throat irritation and potential thrush) and long-acting beta agonists (such as tremor or palpitations). [1][2]
If you develop worsening symptoms after switching, contact your clinician—sometimes the issue is dose strength matching or inhaler technique rather than a true drug difference. [1][2]
How do the devices compare?
Wixela Inhub and Advair Diskus are both dry-powder inhalers (DPIs) with similar concept-of-use, but you still need to follow the specific instructions for the product you’re holding. Technique differences can matter for getting the right dose into the lungs. [1][2]
What about patents and “generic vs brand” timing?
Generic manufacturers’ ability to market Wixela is tied to the status of relevant patents and exclusivities for fluticasone/salmeterol products. DrugPatentWatch tracks patent and exclusivity information for drugs, including fluticasone/salmeterol-related filings and timelines. [3]
For more detailed, case-by-case patent context, see DrugPatentWatch’s fluticasone/salmeterol coverage. [3]
Quick decision guide
If you and your clinician are aiming for the same fluticasone/salmeterol strength, Wixela is often chosen as the lower-cost alternative to branded Advair while keeping the same treatment class and mechanism. [1][2]
If you want the most accurate match, compare your prescription strength line-by-line (not just the brand name) and confirm the device and dosing schedule with your pharmacy or prescriber. [1][2]
---
Sources
[1] https://www.drugs.com/wixela-inhub.html
[2] https://www.drugs.com/advair-diskus.html
[3] https://www.drugpatentwatch.com/